Roy K, Mitsugi K, Sirlin S, Shane B, Sirotnak F M
Program in Molecular Pharmacology and Therapeutics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
J Biol Chem. 1995 Nov 10;270(45):26918-22. doi: 10.1074/jbc.270.45.26918.
L1210 cell variants selected in the presence of the lipophilic dihydrofolate reductase inhibitor, metoprine, expressed increased levels of one-carbon, reduced folate transport inward (Sirotnak, F. M., Moccio, D. M., and Yang, C.-H. (1984) J. Biol. Chem. 259, 13139-13144). Growth of one of these variants (L1210/R69), with metoprine in the presence of decreasing concentrations of 1,L5-CHO-folateH4 (natural diastereoisomer of 5-formyl-tetrahydrofolate), resulted in the selection of other variants (L1210/R82, R83, and R84) with further reduction in one-carbon, reduced folate transport and in two cases (L1210/R83 and R84) with 3-8-fold increased folylpolyglutamate synthetase (FPGS) activity and folate compound polyglutamate formation in situ. Metoprine resistance was further increased, and the requirement for exogenous folate during growth was decreased as well in these variants. The increase in FPGS activity observed in L1210/R83 and R84 was characterized by 3- and 8-fold increases in value for Vmax with no change in Km and the same increase in a 60-61-kDa protein as shown by immunoblotting. Northern blotting revealed the same increases in these two variants in the level of a 2.3-kilobase FPGS mRNA when compared with control, while Southern blotting of genomic DNA did not reveal any increase in FPGS gene-copy number or restriction polymorphisms. Also, no difference in stability of FPGS mRNA was found between parental and variant cells. In contrast, nuclear run-on assays revealed differences among these cell types in the rate of FPGS mRNA transcription that correlated with increased FPGS activity, protein, and mRNA level in the variants. Similar studies with a transport-defective, methotrexate-resistant L1210 cell variant (L1210/R25) documented a 2-3-fold decrease in FPGS activity, protein, and mRNA levels that was accounted for by a decrease in FPGS mRNA transcription. These results provide the first examples of constitutively altered transcriptional regulation of FPGS activity associated with acquired resistance to antifolates.
在亲脂性二氢叶酸还原酶抑制剂美托普林存在的情况下筛选出的L1210细胞变体,其单碳、还原型叶酸向内转运水平升高(西罗特纳克,F.M.,莫乔,D.M.,和杨,C.-H.(1984年)《生物化学杂志》259卷,13139 - 13144页)。这些变体之一(L1210/R69)在美托普林存在且1,L5 - CHO - 叶酸H4(5 - 甲酰基 - 四氢叶酸的天然非对映异构体)浓度逐渐降低的情况下生长,导致筛选出其他变体(L1210/R82、R83和R84),其单碳、还原型叶酸转运进一步降低,在两种情况(L1210/R83和R84)中,叶酰聚谷氨酸合成酶(FPGS)活性以及原位叶酸化合物多聚谷氨酸形成增加3 - 8倍。这些变体中美托普林抗性进一步增强,生长期间对外源叶酸的需求也降低。在L1210/R83和R84中观察到的FPGS活性增加的特征是Vmax值分别增加3倍和8倍,Km无变化,免疫印迹显示60 - 61 kDa蛋白质有相同程度的增加。Northern印迹显示,与对照相比,这两个变体中2.3千碱基FPGS mRNA水平有相同程度的增加,而基因组DNA的Southern印迹未显示FPGS基因拷贝数增加或限制性多态性。此外,在亲本细胞和变体细胞之间未发现FPGS mRNA稳定性的差异。相反,核转录分析显示这些细胞类型在FPGS mRNA转录速率上存在差异,这与变体中FPGS活性、蛋白质和mRNA水平的增加相关。对一种转运缺陷、甲氨蝶呤抗性的L1210细胞变体(L1210/R25)进行的类似研究表明,FPGS活性、蛋白质和mRNA水平降低2 - 3倍,这是由FPGS mRNA转录减少所致。这些结果提供了与获得性抗叶酸药物抗性相关的FPGS活性组成性改变转录调控的首个实例。